We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Btg Plc | LSE:BTG | London | Ordinary Share | GB0001001592 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 840.00 | 839.00 | 840.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
18/1/2018 09:45 | We wont be the ones that foot that bill tho. | king1pin2 | |
18/1/2018 09:15 | 'Obviousness' is a very difficult area of patent law.The US Patent office will have a very detailed protocol for dealing with it and the Appeal court will follow that carefully to ensure that there is real substance behind any appeal.Lots of money for expensive lawyers.The US government interest will be to lower health costs.Not going to be sorted out in the short term! | fhmktg | |
18/1/2018 09:14 | what does it mean “ 30 Months ! stay triggered « | a1ord53 | |
18/1/2018 08:56 | NEW BRUNSWICK, N.J., Jan. 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's Inter Partes Reviews regarding ZYTIGA® (abiraterone acetate): "We are disappointed in and strongly disagree with the U.S. Patent and Trademark Office's (USPTO) decisions relating to ZYTIGA® as part of the Inter Partes Reviews. We are evaluating our options with respect to a request for rehearing and/or appeal to the Court of Appeals for the Federal Circuit. We believe the '438 patent is valid and will continue to vigorously defend it." Inter Partes Review decisions by the USPTO do not result in termination of a 30-month stay triggered under the Hatch-Waxman Act by the timely filing of a patent infringement lawsuit against a generic ANDA applicant. | spyder | |
18/1/2018 08:52 | That's a blow for J&J as well as for our cash flow! | fhmktg | |
18/1/2018 08:47 | No a zytiga patent loss in the US | dp1umb | |
18/1/2018 08:31 | That's a fierce start to the day! Just traders? | fhmktg | |
11/1/2018 17:33 | Wonder who sold the big chunks . Woodford ? | bargainbob | |
11/1/2018 15:38 | And another 200k.... | fhmktg | |
11/1/2018 13:56 | Two buys of 330k....promising! | fhmktg | |
08/1/2018 17:32 | That's the new year down trend under way then . | bargainbob | |
02/1/2018 11:48 | I think BTG has more impact on financials than any external influence . Three years of multi million own goals . Hopefully in the past. Too be fair surprised it not testing the £6 mark yet . | bargainbob | |
02/1/2018 09:20 | Any thoughts on the impact of Trump's tax reforms on BTG's financials.At least there should be some effect from personal tax reductions for the higher income groups on spending on health?Do btg pay us corporation tax on their us activities?Some underpinning of the $/£ exchange rate should help profits in sterling and there may be some further strengthening of the dollar. | fhmktg | |
29/12/2017 11:33 | Very satisfying year end, I'm showing a near 32% rise over the year.All the best to holders for 2018! | fhmktg | |
28/12/2017 09:21 | Thanks, different meaning up in Scotland lol Patients are the number one priority at ASD Healthcare. We affirm this commitment daily in our True Blue culture—which is our way of delivering exceptional services to our healthcare partners and the patients they serve. Many people define True Blue as a loyal, dependable and trustworthy person whom others count on. At ASD Healthcare, our associates put those words into action each day by going above and beyond expectations. Our innovative products and exceptional customer service make us the largest distributor of oncology and supportive care products to healthcare facilities and specialty pharmacies. Our knowledge, reach and partnerships position us as the number one distributor of blood derivatives, nephrology products and critical specialty pharmaceutical products in the U.S. We maintain solid relationships with all major specialty pharmaceutical manufacturers, and are the trusted partner of all major GPOs. That’s why 95 percent of U.S. hospitals are our active customers, and why other healthcare providers depend on us to deliver innovative products and services. When founded in 1993, ASD Healthcare was originally known as Alternate Site Distributors. Our name was changed to Advanced Specialty Distribution (ASD) in 1997, when our customer base expanded to health systems. Then a subsidiary of Bergen Brunswick Drug Corporation, ASD Healthcare became a part of AmerisourceBergen Specialty Group when AmerisourceBergen Corporation was formed in 2001. | bargainbob | |
28/12/2017 09:00 | Ps do you have a link , tried to find it , only found a few cartoon like videos . | bargainbob | |
28/12/2017 08:54 | Does it say what year fhmktg lol | bargainbob | |
28/12/2017 08:47 | BTG have a countdown clock on their US Varithena site ready for Jan 1st.It lists the cpt codes and allows customers to download a registration form, plus guidance to practitioners on how to order the product.Creative positive marketing suited to the US market. | fhmktg | |
20/12/2017 17:26 | Like everything Louise says she at least 5 years out. | bargainbob | |
20/12/2017 13:41 | Telegraph today says that Shire are being looked at by a number of major pharma companies with a suggested price of £50 per share.In the early days of BTG Louise said her aim was to be the next Shire to emerge in the UK with ftse100 entry by 2021.Pure speculation from that to my year end mouldering at what a £50 take out price for btg could be worth. Happy Holidays! | fhmktg | |
20/12/2017 12:36 | Meldex said the same look at that now 0p | bargainbob | |
20/12/2017 10:53 | Am I missing the obvious? Please enlighten. | ashehzi | |
20/12/2017 09:50 | Shire in the takeover frame at £50 per share!If being the 'next Shire' is Louise's dream, then bring it on!( Man was born to dream)Happy Holidays! | fhmktg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions